Takeshi Araki
Maebashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
NLRP3 inflammasome activation is associated with type 1 inflammation and neutrophil activation in pyoderma gangrenosum across human and murine models.
Journal: JID innovations : skin science from molecules to population health
Published: December 29, 2025
Protective effects of the selective JAK2/3 inhibitor AG490 against ulcer formation following cutaneous ischemia-reperfusion injury.
Journal: Journal of dermatological science
Published: October 14, 2025
Maintenance of Early Responses and Delayed Responses to Tralokinumab Treatment in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: September 17, 2025
Effectiveness and Prognosis of Systemic Chemotherapy for Unresectable Malignant Apocrine and Eccrine Tumors: A Real-World Multicenter Retrospective Study.
Journal: JCO global oncology
Published: September 12, 2025
Oxidative stress induced TSLP production via TRPV4 regulates type 2 inflammation and pruritus in MC903 induced atopic dermatitis mouse model.
Journal: Journal of dermatological science
Published: September 03, 2025
Atypical Deep Dermatophytosis Caused by Trichophyton Rubrum: A Case Report and Literature Review.
Journal: The Journal of dermatology
Published: August 01, 2025
Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: July 25, 2025
Thirty-Six-Week Real-World Effectiveness of Lebrikizumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: Results from a Prospective Japanese Study.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: July 25, 2025
Real world experience of switching from tralokinumab to lebrikizumab: Author's reply.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 06, 2025
Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: April 09, 2025
A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus systemic therapy-experienced patients.
Journal: Journal of the American Academy of Dermatology
Published: March 23, 2025
Last Updated: 09/26/2026